CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02486367
NCT02486367Phase 4Completed
CompareCT.gov

Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)

University Hospitals Cleveland Medical Center·interventional·Posted Jul 1, 2015·Updated Jul 20, 2022

In Brief

A Phase 4 clinical trial evaluating Clopidogrel and Ticagrelor for Aortic Stenosis and 2 related conditions. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The central hypothesis of this study is that TAVR leads to platelet deposition and inflammatory cell activation that can be attenuated by the potent anti-platelet and/or pleiotropic effects of ticagrelor. This single center, prospective randomized trial addresses the following specific aims: 1. To determine whether high-potency ADP receptor blockade reduces measures of platelet activation in patients after TAVR. 2. To determine whether high-potency ADP receptor blockade mitigates the pro-thrombotic inflammatory response observed after TAVR.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Stenosis, Inflammation, Thrombosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 1, 2015
Enrollment StartJun 1, 2015
Primary CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.0 years ago

Interventions

Clopidogreldrug

Standard ADP receptor blockade

Ticagrelordrug

High potency ADP receptor blockade